Erasca(ERAS) GlobeNewswire·2025-03-20 20:01Core Insights - Erasca, Inc. is advancing its RAS-targeting franchise with two promising candidates, ERAS-0015 and ERAS-4001, expected to enter clinical trials in 2025 [1][2] - The ongoing Phase 3 SEACRAFT-2 trial is progressing well, with randomized data anticipated in the second half of 2025 [1][2] - The company has a robust financial position, with cash, cash equivalents, and marketable securities totaling 440 million as of December 31, 2024, which is expected to fund operations into the second half of 2027 [1][9][10] RAS-Targeting Franchise - The RAS-targeting franchise includes ERAS-0015, a potential best-in-class pan-RAS molecular glue, and ERAS-4001, a potential first-in-class pan-KRAS inhibitor, both addressing significant unmet medical needs in various cancers [2][5] - The SEACRAFT-2 trial has received FDA Fast Track Designation for NRASm melanoma, positioning it as a potential first-to-market therapy in a high unmet need area [2][5] Research and Development Highlights - The company has made significant progress in its RAS-targeting programs, with key activities completed to support IND submissions for both ERAS-0015 and ERAS-4001 [5] - Initial Phase 1b data for naporafenib plus trametinib in melanoma showed promising efficacy and tolerability, reinforcing the rationale for the ongoing SEACRAFT-2 trial [5][6] Financial Performance - R&D expenses for Q4 2024 were 26.1 million, up from 24.8 million in Q4 2023, driven by clinical trial and preclinical study costs [11] - For the full year 2024, R&D expenses totaled 115.4 million, compared to 32.2 million, compared to 161.7 million, or $(0.69) per share [13][20] Corporate Developments - The company strengthened its leadership team with key appointments in medical affairs and clinical development, enhancing its capabilities in oncology [10] - Upcoming milestones include IND filings for ERAS-0015 and ERAS-4001 in mid-Q2 and Q2 2025, respectively, with initial Phase 1 data expected in 2026 [10][8]